Clinical trials for the safety and efficacy of the combination of XELOX,the colorectal cancer radical resection adjuvant chemotherapy and of chronic hepatitis therapeutic agent 3 oxygelmillpropionic acid polymer.(Phase 1 test)
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2637700
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: The dose of Seroshion is 1 capsule (10mg) after each meal,three times a day.We start the Seroshion administration at the first day of the chemotherapy,and also continue to intake it ,if you don’t continue the chemotherapy. The end of chemotherapy is the end of Seroshion.
Primary outcome(s): safety
Study Design: Single arm Non-randomized
创建时间：
2016-05-15
